Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$92.34K | – |
See a number that looks wrong?